Nkarta, Inc. Common Stock
NKTXNkarta, Inc. is a biotechnology company focused on developing allogeneic CAR NK (natural killer) cell therapies for cancer treatment. Leveraging its proprietary cell engineering platform, Nkarta aims to create off-the-shelf immunotherapies to improve efficacy and safety for patients with various cancers.
Company News
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies, announced its participation in the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025.
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies, announced its participation in the 7th Annual Evercore HealthCONx Conference on December 4, 2024.
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024.
Nkarta's stock surged 11.1% after Raymond James upgraded the stock to a strong buy, citing the company's strong cash position and the potential of its lead candidate NKX019 in treating autoimmune diseases.
Nkarta, a biopharmaceutical company, announced changes to its leadership team, including the appointment of Nadir Mahmood as President and the promotion of David R. Shook to Chief Medical Officer and Head of Research & Development.
